Arixtra®
Fondaparinux is a synthetic pentasaccharide that selectively inhibits Factor Xa via antithrombin III. Used for DVT/PE prophylaxis and treatment.
| Dosage Form | SC Injectable (Prefilled Syringe) |
| Strength | 2.5 mg, 5 mg, 7.5 mg, 10 mg |
| Storage | Store at 25°C. Do not freeze. |
| Category | Cardiovascular |
| Availability | Available for Transfer |
DVT prophylaxis in hip fracture, hip/knee replacement, and abdominal surgery; treatment of DVT and PE.
Selective Factor Xa inhibitor that binds to antithrombin III, catalyzing Factor Xa neutralization without directly affecting thrombin.
Each Burrard Pharmaceuticals technology transfer package for Fondaparinux includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier sections for a named territory, scoped per programme.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Scope and timing for the complete know-how package are confirmed in writing after a confidentiality agreement. Book a consultation to discuss your specific requirements.